Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (589549) 589549
Newsletter (54234) 54234
Newspaper Article (17517) 17517
Magazine Article (2875) 2875
Conference Proceeding (1269) 1269
Book / eBook (877) 877
Dissertation (601) 601
Web Resource (382) 382
Transcript (299) 299
Book Chapter (176) 176
Reference (166) 166
Publication (131) 131
Streaming Video (112) 112
Government Document (104) 104
Journal / eJournal (38) 38
Book Review (26) 26
Report (7) 7
Paper (4) 4
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (466645) 466645
science & technology (366303) 366303
life sciences & biomedicine (350330) 350330
antineoplastic agents (259062) 259062
female (223959) 223959
oncology (190134) 190134
male (183977) 183977
biological and medical sciences (182489) 182489
medical sciences (177535) 177535
cancer (150133) 150133
middle aged (140892) 140892
animals (139271) 139271
antimitotic agents (133495) 133495
pharmacology. drug treatments (131886) 131886
aged (116350) 116350
adult (113733) 113733
antineoplastic agents - therapeutic use (108263) 108263
chemotherapy (107174) 107174
antineoplastic combined chemotherapy protocols - therapeutic use (106454) 106454
antineoplastic agents - pharmacology (100916) 100916
care and treatment (88331) 88331
research (78869) 78869
mice (75822) 75822
tumors (73361) 73361
cell line, tumor (73299) 73299
treatment outcome (67805) 67805
pharmacology & pharmacy (63950) 63950
prognosis (43040) 43040
antineoplastic agents - administration & dosage (42981) 42981
combined modality therapy (42639) 42639
neoplasms - drug therapy (41829) 41829
antineoplastic agents - adverse effects (40551) 40551
health aspects (40294) 40294
analysis (40193) 40193
apoptosis (38806) 38806
oncology, experimental (37591) 37591
apoptosis - drug effects (37184) 37184
aged, 80 and over (36398) 36398
hematology (36367) 36367
breast neoplasms - drug therapy (35996) 35996
dose-response relationship, drug (34707) 34707
drug therapy (34675) 34675
antineoplastic agents - chemistry (33811) 33811
breast cancer (32914) 32914
general aspects (32213) 32213
neoplasm staging (31322) 31322
antineoplastic combined chemotherapy protocols - adverse effects (31011) 31011
cell proliferation - drug effects (31007) 31007
abridged index medicus (30376) 30376
adolescent (30317) 30317
biochemistry & molecular biology (29606) 29606
retrospective studies (29273) 29273
tumor cells, cultured (29192) 29192
chemistry (28199) 28199
lung neoplasms - drug therapy (27577) 27577
time factors (26657) 26657
cell survival - drug effects (25871) 25871
medicine & public health (25794) 25794
physical sciences (25697) 25697
survival rate (25158) 25158
disease-free survival (24454) 24454
metastasis (23442) 23442
child (23198) 23198
follow-up studies (22957) 22957
cisplatin - administration & dosage (22920) 22920
rats (22079) 22079
survival analysis (22063) 22063
antineoplastic combined chemotherapy protocols - administration & dosage (21931) 21931
drug screening assays, antitumor (21210) 21210
drug administration schedule (21053) 21053
breast neoplasms - pathology (20882) 20882
immunotherapy (20295) 20295
drugs (19907) 19907
doxorubicin - administration & dosage (19522) 19522
chemotherapy, adjuvant (19502) 19502
surgery (19016) 19016
mice, nude (19013) 19013
antineoplastic agents, phytogenic - pharmacology (18873) 18873
drug resistance, neoplasm (18857) 18857
structure-activity relationship (18703) 18703
chemistry, medicinal (18626) 18626
fluorouracil - administration & dosage (18573) 18573
antineoplastic agents - chemical synthesis (17962) 17962
clinical trials as topic (17876) 17876
risk factors (17720) 17720
cell biology (17532) 17532
clinical trials (16644) 16644
cancer therapies (16596) 16596
molecular structure (16554) 16554
hematology, oncology and palliative medicine (16541) 16541
neoplasm metastasis (16150) 16150
genetic aspects (15789) 15789
medical research (15724) 15724
cyclophosphamide - administration & dosage (15710) 15710
universities and colleges (15429) 15429
xenograft model antitumor assays (15202) 15202
drug resistance (15173) 15173
remission induction (15120) 15120
pharmaceutical industry (14987) 14987
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (456) 456
Online Resources - Online (375) 375
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (56) 56
Collection Dvlpm't (Acquisitions) - Vendor file (46) 46
Collection Dvlpm't (Acquisitions) - Closed Orders (36) 36
UofT at Mississauga - Stacks (16) 16
Gerstein Science - Periodical Stacks (14) 14
Scarborough Hospital - Online (6) 6
Chemistry (A D Allen) - Stacks (5) 5
Scarborough Hospital - Birchmount (5) 5
Lakeridge Health Sciences - Online (4) 4
Gerstein Science - Bindery (3) 3
Robarts - Stacks (3) 3
St. Michael's Hospital - Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Reference (3) 3
UTL at Downsview - May be requested (3) 3
Credit Valley Hospital - Stacks (2) 2
East Asian (Cheng Yu Tung) - Reference (2) 2
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Baycrest Hospital - Wellness Library (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Theses (1) 1
Humber River Regional Hospital - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Pharmacy (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (631866) 631866
Japanese (20129) 20129
French (7954) 7954
Chinese (7656) 7656
Russian (5384) 5384
German (5056) 5056
Italian (2634) 2634
Spanish (1575) 1575
Polish (1559) 1559
Portuguese (878) 878
Hungarian (725) 725
Czech (666) 666
Danish (390) 390
Dutch (336) 336
Norwegian (267) 267
Swedish (242) 242
Ukrainian (179) 179
Korean (163) 163
Hebrew (162) 162
Finnish (139) 139
Croatian (130) 130
Bulgarian (124) 124
Serbian (121) 121
Slovak (84) 84
Romanian (79) 79
Turkish (30) 30
Lithuanian (28) 28
Bosnian (13) 13
Greek (7) 7
Afrikaans (3) 3
Slovenian (3) 3
Icelandic (2) 2
Amharic (1) 1
Arabic (1) 1
Breton (1) 1
Catalan (1) 1
Kurdish (1) 1
Latin (1) 1
Manx (1) 1
Nauru (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Anti-cancer drug design
Cancer Research Campaign (Great Britain)
Anti-cancer drug design, ISSN 0266-9536, 1985
Antineoplastic agents | Chemotherapy | Cancer
Journal
Details down arrow
2. From local invasion to metastatic cancer
: involvement of distant sites through the lymphovascular system
by Leong, Stanley P.L
2009, ISBN 9781603270861, xxviii, 637
Neoplasms Invasiveness | Neoplasm Metastasis | Lymphangiogenesis - drug effects
Book
Details down arrow
3. Cancer chemotherapy and pharmacology
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 1978
Chemotherapy | Cancer
Journal
Details down arrow
4. Full Text Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
by Touil, Yasmine S and Touil, Yasmine S and Seguin, Johanne and Seguin, Johanne and Scherman, Daniel and Scherman, Daniel and Chabot, Guy G and Chabot, Guy G
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Pneumology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Anti-cancer drugs
Anti-cancer drugs, ISSN 0959-4973, 1990
Antineoplastic agents | Chemotherapy | Cancer
Journal
Details down arrow
6. PIPAC: Pressurized intraperitoneal aerosol chemotherapy - Cancer under pressure
by Reymond, Marc A and Solass, Wiebke
01/2014, ISBN 9783110345940
Book
Details down arrow
7. Molecular cancer therapeutics
American Association for Cancer Research
Molecular cancer therapeutics, ISSN 1535-7163, 2001
Prevention | Treatment | Therapeutics | Cancer
Journal
Details down arrow
8. Full Text Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
by Lancet, Jeffrey E and Cortes, Jorge E and Hogge, Donna E and Tallman, Martin S and Kovacsovics, Tibor J and Damon, Lloyd E and Komrokji, Rami and Solomon, Scott R and Kolitz, Jonathan E and Cooper, Maureen and Yeager, Andrew M and Louie, Arthur C and Feldman, Eric J
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Life Sciences & Biomedicine | Hematology | Science & Technology | Daunorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Liposomes | Daunorubicin - administration & dosage | Index Medicus | Abridged Index Medicus | 33 | 8 | Clinical Trials and Observations | 29
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
by Stephen Johnston and John Pippen, Jr and Xavier Pivot and Mikhail Lichinitser and Saeed Sadeghi and Veronique Dieras and Henry Leonidas Gomez and Gilles Romieu and Alexey Manikhas and M. John Kennedy and Michael F. Press and Julie Maltzman and Allison Florance and Lisa O'Rourke and Cristina Oliva and Steven Stein and Mark Pegram
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
by Hellmann, Matthew D and Paz-Ares, Luis and Bernabe Caro, Reyes and Zurawski, Bogdan and Kim, Sang-We and Carcereny Costa, Enric and Park, Keunchil and Alexandru, Aurelia and Lupinacci, Lorena and de la Mora Jimenez, Emmanuel and Sakai, Hiroshi and Albert, Istvan and Vergnenegre, Alain and Peters, Solange and Syrigos, Konstantinos and Barlesi, Fabrice and Reck, Martin and Borghaei, Hossein and Brahmer, Julie R and O’Byrne, Kenneth J and Geese, William J and Bhagavatheeswaran, Prabhu and Rabindran, Sridhar K and Kasinathan, Ravi S and Nathan, Faith E and Ramalingam, Suresh S
The New England journal of medicine, ISSN 0028-4793, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. False hope
: bone marrow transplantation for breast cancer
2007, ISBN 9780195187762, ix, 355
Book
Details down arrow
12. Full Text 6-(Hetero)Arylpurine nucleotides as inhibitors of the oncogenic target DNPH1: Synthesis, structural studies and cytotoxic activities
by Amiable, Claire and Paoletti, Julie and Haouz, Ahmed and Padilla, André and Labesse, Gilles and Kaminski, Pierre-Alexandre and Pochet, Sylvie
European journal of medicinal chemistry, ISSN 0223-5234, 10/2014, Volume 85, pp. 418 - 437
Inhibitor | Cross-coupling reaction | DNPH1 | Nucleoside analogues | Crystal structure | Cancer | Purine Nucleotides - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Molecular Targeted Therapy | Purine Nucleotides - chemistry | N-Glycosyl Hydrolases - chemistry | Purine Nucleotides - metabolism | Antineoplastic Agents - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Chemistry Techniques, Synthetic | Enzyme Inhibitors - metabolism | N-Glycosyl Hydrolases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Nuclear Proteins - metabolism | Purine Nucleotides - chemical synthesis | Antineoplastic Agents - chemistry | Nuclear Proteins - chemistry | N-Glycosyl Hydrolases - metabolism | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Conformation | Molecular Docking Simulation | Drug Screening Assays, Antitumor | Enzymes | Colon cancer | Leukemia | Crystals | Hydrolases | Nucleotides | Structure | Index Medicus | Nuclear Proteins/chemistry | Purine Nucleotides/metabolism | Proto-Oncogene Proteins/antagonists & inhibitors | Enzyme Inhibitors/metabolism | Enzyme Inhibitors/pharmacology | Life Sciences | Antineoplastic Agents/pharmacology | N-Glycosyl Hydrolases/antagonists & inhibitors | Nuclear Proteins/antagonists & inhibitors | N-Glycosyl Hydrolases/metabolism | Nuclear Proteins/metabolism | Purine Nucleotides/chemistry | Enzyme Inhibitors/chemistry | Purine Nucleotides/chemical synthesis | Enzyme Inhibitors/chemical synthesis | Antineoplastic Agents/metabolism | N-Glycosyl Hydrolases/chemistry | Proto-Oncogene Proteins/chemistry | Biochemistry, Molecular Biology | Proto-Oncogene Proteins/metabolism | Purine Nucleotides/pharmacology | Antineoplastic Agents/chemistry | Antineoplastic Agents/chemical synthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
by Alba, E and Calvo, L and Albanell, J and De la Haba, J.R and Arcusa Lanza, A and Chacon, J.I and Sanchez-Rovira, P and Plazaola, A and Lopez Garcia-Asenjo, J.A and Bermejo, B and Carrasco, E and Lluch, A and on behalf of GEICAM and GEICAM
Annals of oncology, ISSN 0923-7534, 12/2012, Volume 23, Issue 12, pp. 3069 - 3074
luminal breast cancer | neoadjuvant | hormonotherapy | chemotherapy | Neoadjuvant | Chemotherapy | Hormonotherapy | Luminal breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Receptors, Progesterone - metabolism | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Taxoids - adverse effects | ErbB Receptors - metabolism | Docetaxel | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Keratin-8 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Keratin-18 - metabolism | Neoadjuvant Therapy - adverse effects | Epirubicin - therapeutic use | Aged | Antineoplastic Agents, Alkylating - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
by Kazuki N. Sugahara and Tambet Teesalu and Priya Prakash Karmali and Venkata Ramana Kotamraju and Lilach Agemy and Daniel R. Greenwald and Erkki Ruoslahti
Science (American Association for the Advancement of Science), ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Drug therapy | Health aspects | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights